{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:44:59Z","timestamp":1760060699712,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203294"],"award-info":[{"award-number":["82203294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteosarcoma primarily occurs in children and adolescents, and is a highly aggressive bone tumor, particularly presenting challenges in metastatic or recurrent cases due to chemoresistance. Emerging evidences suggest that histone deacetylase inhibitors (HDACis) may exert anti-tumor effects by enhancing the efficacy of various therapeutic modalities. However, the combination of traditional chemotherapy with HDACi-based treatment for osteosarcoma intervention has not been thoroughly explored. This study investigates the anticancer properties of HDACis and\/or etoposide (VP16) on the osteosarcoma cell lines U2OS and SJSA-1. Cell viability, morphology, growth and apoptosis were evaluated after treatments, in addition to their influence on the expression levels of proteins associated with apoptotic processes. To elucidate the underlying mechanisms, we employed RNA sequencing, RT-qPCR, and Western blot analyses. Treatment with either HDACis or VP16 alone resulted in an antiproliferative effects in U2OS and SJSA-1 cell lines. Notably, HDACis significantly increased the sensitivity of osteosarcoma cells to VP16, as evidenced by marked differences in cell viability, growth, morphology and apoptosis. Furthermore, when compared to doxorubicin treatment, this VP16\/TSA\/NAM combinatory regimen demonstrated a comparable ability to suppress cell viability while exhibiting a more pronounced inhibition of cell proliferation. Mechanistically, the combination of HDACis and VP16 specifically resulted in inhibition of the Hippo\/YAP signaling cascade, accompanied by a reduction in total YAP1 protein expression. Collectively, our findings suggest that HDACis potentiate the capacity of VP16 to hinder cellular proliferation and trigger apoptosis via the downregulation of the Hippo\/YAP pathway, thereby providing a prospective approach to overcome chemoresistance in osteosarcoma.<\/jats:p>","DOI":"10.3390\/ijms26188935","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:33:02Z","timestamp":1758007982000},"page":"8935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HDAC Inhibitors Enhance the Chemosensitivity of Osteosarcoma Cells to Etoposide by Suppressing the Hippo\/YAP Signaling Pathway"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-7144","authenticated-orcid":false,"given":"Zhijie","family":"Cao","sequence":"first","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulu","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengshan","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"},{"name":"Institute of Public Health, School of Medicine, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianjin","family":"Fan","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"},{"name":"Institute of Public Health, School of Medicine, Nankai University, Tianjin 300071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Jin","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-2518","authenticated-orcid":false,"given":"Yajing","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-6902","authenticated-orcid":false,"given":"Yanwen","family":"Xiong","sequence":"additional","affiliation":[{"name":"National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglai","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Common Mechanism Research for Major Diseases & Department of Medical Genetics, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/14737140.2018.1413939","article-title":"Current and future therapeutic approaches for osteosarcoma","volume":"18","author":"Harrison","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yu, L., Zhang, J., and Li, Y. (2022). Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.871076"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"215887","DOI":"10.1016\/j.canlet.2022.215887","article-title":"Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential","volume":"547","author":"Wen","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n, V., Villamayor, M.L., Chamorro, J., Rosero, D.I., Pozas, J., San Rom\u00e1n, M., Calvo, J.C., P\u00e9rez de Aguado, P., Moreno, J., and Guerrero, P. (2022). Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213784"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e202420671","DOI":"10.1002\/anie.202420671","article-title":"Visible-Light Photocatalyzed Skeletal Rearrangement Enables the Synthesis of Highly Functionalized Xanthenes with Antitumor Activity","volume":"64","author":"Lin","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115605","DOI":"10.1016\/j.bone.2020.115605","article-title":"Clinical efficiency of epigenetic drugs therapy in bone malignancies","volume":"143","author":"Ruosi","year":"2021","journal-title":"Bone"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113825","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: From molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1002\/ijc.33046","article-title":"Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma","volume":"147","author":"McGuire","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/B:APPT.0000038037.68908.6e","article-title":"Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells","volume":"9","author":"Roh","year":"2004","journal-title":"Apoptosis"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Magar, A.G., Morya, V.K., Koh, Y.-H., and Noh, K.-C. (2025). Synergistic HDAC4\/8 Inhibition Sensitizes Osteosarcoma to Doxorubicin via pAKT\/RUNX2 Pathway Modulation. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083574"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7150\/ijbs.16569","article-title":"Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation","volume":"12","author":"Deng","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nikas, I.P., Paschou, S.A., and Ryu, H.S. (2020). The Role of Nicotinamide in Cancer Chemoprevention and Therapy. Biomolecules, 10.","DOI":"10.3390\/biom10030477"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pan.2013.01.001","article-title":"Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras\/Akt pathways","volume":"13","author":"Zhang","year":"2013","journal-title":"Pancreatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s11033-014-3246-y","article-title":"Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells","volume":"41","author":"Jafary","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s13277-013-1356-0","article-title":"The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells","volume":"35","author":"Jafary","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Bernab\u00e9, A., Tarrag\u00f3-Celada, J., Cunin, V., Michelland, S., Cort\u00e9s, R., Poignant, J., Boyault, C., Rachidi, W., Bourgoin-Voillard, S., and Cascante, M. (2021). Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073378"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","article-title":"Enhancing the apoptotic and therapeutic effects of HDAC inhibitors","volume":"280","author":"Frew","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2017.06.006","article-title":"Therapeutic applications of histone deacetylase inhibitors in sarcoma","volume":"59","author":"Tang","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jang, J.Y., Kim, D., Im, E., and Kim, N.D. (2025). Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020796"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/CAD.0000000000000256","article-title":"Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines","volume":"26","author":"Unland","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1038\/sj.onc.1210976","article-title":"Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells","volume":"27","author":"Hajji","year":"2008","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13046-021-02125-z","article-title":"Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis","volume":"40","author":"Schmidt","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"155459","DOI":"10.1016\/j.phymed.2024.155459","article-title":"Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression","volume":"126","author":"Chen","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3892\/ol.2013.1400","article-title":"Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis","volume":"6","author":"Wang","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Smith, K.H., Trovillion, E.M., Sholler, C., Gandra, D., McKinney, K.Q., Mulama, D., Dykema, K.J., Nagulapally, A.B., Oesterheld, J., and Saulnier Sholler, G.L. (2024). Panobinostat Synergizes with Chemotherapeutic Agents and Improves Efficacy of Standard-of-Care Chemotherapy Combinations in Ewing Sarcoma Cells. Cancers, 16.","DOI":"10.3390\/cancers16213565"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"28420","DOI":"10.18632\/oncotarget.8546","article-title":"MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene","volume":"7","author":"Pu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100712","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1369\/jhc.2008.952044","article-title":"Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma","volume":"57","author":"Bressenot","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1158\/0008-5472.CAN-19-0840","article-title":"Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance","volume":"79","author":"Bernard","year":"2019","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zeng, R., and Dong, J. (2021). The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers, 13.","DOI":"10.3390\/cancers13020318"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kumar, R., and Hong, W. (2024). Hippo Signaling at the Hallmarks of Cancer and Drug Resistance. Cells, 13.","DOI":"10.3390\/cells13070564"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.molcel.2022.03.027","article-title":"WWC proteins mediate LATS1\/2 activation by Hippo kinases and imply a tumor suppression strategy","volume":"82","author":"Qi","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1002\/mco2.375","article-title":"Targeting Hippo signaling in cancer: Novel perspectives and therapeutic potential","volume":"4","author":"Lv","year":"2023","journal-title":"MedComm"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40880-016-0109-z","article-title":"Hippo\/YAP signaling pathway is involved in osteosarcoma chemoresistance","volume":"35","author":"Wang","year":"2016","journal-title":"Chin. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Xia, Y., Zhang, Y.L., Yu, C., Chang, T., and Fan, H.Y. (2014). YAP\/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109575"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/1078-0432.CCR-14-2191","article-title":"The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2018.06.021","article-title":"Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines","volume":"433","author":"Ferraiuolo","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wang, Y., Zhai, Y., Yuan, Y., Wang, J., Jin, Y., Dang, L., Song, L., Chen, C., and Wang, Y. (2023). Cinobufacini injection suppresses the proliferation of human osteosarcoma cells by inhibiting PIN1-YAP\/TAZ signaling pathway. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1081363"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Morice, S., Mullard, M., Brion, R., Dupuy, M., Renault, S., Tesfaye, R., Brounais-Le Royer, B., Ory, B., Redini, F., and Verrecchia, F. (2020). The YAP\/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth. Cancers, 12.","DOI":"10.3390\/cancers12123847"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1080\/15384101.2019.1568743","article-title":"Spontaneous formation of tumorigenic hybrids between human omental adipose-derived stromal cells and endometrial cancer cells increased motility and heterogeneity of cancer cells","volume":"18","author":"Li","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_44","first-page":"1205","article-title":"Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models","volume":"92","author":"Pacheco","year":"2017","journal-title":"Arch. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/j.1745-7254.2007.00662.x","article-title":"Interferon-\u03b1 enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis","volume":"28","author":"Yuan","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"eabf4148","DOI":"10.1126\/sciadv.abf4148","article-title":"An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation","volume":"7","author":"Cao","year":"2021","journal-title":"Sci. Adv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:07Z","timestamp":1760035507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":46,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26188935"],"URL":"https:\/\/doi.org\/10.3390\/ijms26188935","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2025,9,13]]}}}